Income Statement Scinai Immunotherapeutics Ltd.

Stocks

SCNI

US09073Q3039

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:31:56 2026-08-04 EDT			5-day change	1st Jan Change
0.2560 ^USD	-6.23%		+2.16%	-62.13%

06-15	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Scinai Immunotherapeutics Ltd. Appoints Eilon Elmalem as Site Head of Yavne Cdmo Facility, Effective June 14, 2026	CI

23.ocY_tA_ScQryOT6sQwdAhvEQx1oYPvlTgb1-RhtTwgo.7Zlv92STI1m4WEf9d1IK9qJKkTBAa8oi0IQ5Ny8gqE-XiA7BaqU1Pa1jcw

Published financial data: SCINAI IMMUNOTHERAPEUTICS LTD.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Revenues	-	-	-	658K	1.31M
Total Revenues	-	-	-	658K	1.31M
Cost of Goods Sold, Total	-	-	-	1.24M	3.96M
Gross Profit	-	-	-	-580K	-2.65M
Selling General & Admin Expenses, Total	24.53M	5.3M	4.5M	2.53M	2.52M
R&D Expenses	10.34M	5.76M	5.21M	5.53M	2.37M
Other Operating Expenses	-40K	-	-9K	-	-
Other Operating Expenses, Total	34.83M	11.06M	9.71M	8.06M	4.89M
Operating Income	-34.83M	-11.06M	-9.71M	-8.64M	-7.54M
Interest Expense, Total	-10.83M	-4.89M	-	-1.42M	-359K
Interest And Investment Income	3K	8.13M	123K	100K	20K
Net Interest Expenses	-10.83M	3.24M	123K	-1.32M	-339K
Currency Exchange Gains (Loss)	5.71M	1.52M	-933K	-84K	-419K
Other Non Operating Income (Expenses)	-33K	497K	4.02M	81K	-7K
EBT, Excl. Unusual Items	-39.98M	-5.8M	-6.5M	-9.96M	-8.31M
Gain (Loss) On Sale Of Investments	-	-	-	-	-
Other Unusual Items	-	-	-	14.76M	-
EBT, Incl. Unusual Items	-39.98M	-5.8M	-6.5M	4.8M	-8.31M
Earnings From Continuing Operations	-39.98M	-5.8M	-6.5M	4.8M	-8.31M
Net Income to Company	-39.98M	-5.8M	-6.5M	4.8M	-8.31M
Net Income - (IS)	-39.98M	-5.8M	-6.5M	4.8M	-8.31M
Preferred Dividend and Other Adjustments	-	-	-	4.8M	-
Net Income to Common Incl Extra Items	-39.98M	-5.8M	-6.5M	0	-8.31M
Net Income to Common Excl. Extra Items	-39.98M	-5.8M	-6.5M	0	-8.31M
Per Share Items
Net EPS - Basic	-283.24	-30.74	-16.64	-	-3.56
Basic EPS - Continuing Operations	-283.24	-30.74	-16.64	-	-3.56
Basic Weighted Average Shares Outstanding	141K	189K	391K	806K	2.33M
Net EPS - Diluted	-283.24	-40	-16.64	-	-3.56
Diluted EPS - Continuing Operations	-283.24	-40	-16.64	-	-3.56
Diluted Weighted Average Shares Outstanding	141K	189K	391K	806K	2.33M
Normalized Basic EPS	-177.03	-19.22	-10.4	-7.72	-2.22
Normalized Diluted EPS	-177.03	-19.22	-10.4	-7.72	-2.22
American Depositary Receipts Ratio (ADR)	4K	4K	4K	4K	4K
Supplemental Items
EBITDA	-33.31M	-10.5M	-9.19M	-6.99M	-6.12M
EBITA	-34.83M	-11.06M	-9.71M	-8.64M	-7.54M
EBIT	-34.83M	-11.06M	-9.71M	-8.64M	-7.54M
EBITDAR	-	-	-	-	-
Normalized Net Income	-24.99M	-3.62M	-4.06M	-6.23M	-5.19M
Interest on Long-Term Debt	10.83M	4.89M	2.97M	1.42M	33K
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	10.34M	5.76M	5.21M	5.53M	2.37M
Net Rental Expense, Total	-	-	-	-	-
Stock-Based Comp., COGS (Total)	-	-	-	-	182K
Stock-Based Comp., R&D Exp. (Total)	1.04M	100K	107K	322K	-48K
Stock-Based Comp., SG&A Exp. (Total)	7.86M	1.5M	1.03M	360K	170K
Total Stock-Based Compensation	8.9M	1.6M	1.14M	682K	304K

Fiscal Period: December	2021	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	54.04M	14.08M	4.87M	1.96M	1.66M
Short Term Investments	-	-	-	-	-
Trading Asset Securities, Total	-	-	-	-	-
Total Cash And Short Term Investments	54.04M	14.08M	4.87M	1.96M	1.66M
Accounts Receivable, Total	-	-	-	83K	73K
Other Receivables	306K	110K	366K	134K	95K
Total Receivables	306K	110K	366K	217K	168K
Prepaid Expenses	706K	45K	71K	79K	75K
Restricted Cash	-	140K	140K	131K	150K
Other Current Assets, Total	-	-	-	-	-
Total Current Assets	55.05M	14.37M	5.45M	2.39M	2.05M
Gross Property Plant And Equipment	53.51M	15.12M	14.83M	15.51M	15.45M
Accumulated Depreciation	-9.4M	-2.42M	-2.81M	-4.46M	-5.88M
Net Property Plant And Equipment	44.11M	12.7M	12.02M	11.06M	9.57M
Long-term Investments	-	-	-	-	-
Other Long-Term Assets, Total	444K	-	-	-	-
Total Assets	99.6M	27.07M	17.47M	13.45M	11.63M
Liabilities
Accounts Payable, Total	3.11M	716K	535K	376K	407K
Accrued Expenses, Total	3.33M	1.24M	849K	781K	759K
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	773K	382K	396K	424K	329K
Unearned Revenue Current, Total	-	-	-	225K	90K
Total Current Liabilities	7.21M	2.34M	1.78M	1.81M	1.58M
Long-Term Debt	63.25M	20.08M	19.37M	260K	294K
Long-Term Leases	5.71M	1.08M	797K	1.4M	1.64M
Unearned Revenue Non Current	-	-	-	-	-
Pension & Other Post Retirement Benefits	95K	-	-	-	-
Other Non Current Liabilities	-	5.33M	96K	3K	-
Total Liabilities	76.27M	28.83M	22.04M	3.47M	3.52M
Preferred Stock Redeemable	-	-	-	5.63M	5.63M
Total Preferred Equity	-	-	-	5.63M	5.63M
Additional Paid In Capital	388M	116M	120M	124M	130M
Retained Earnings	-365M	-116M	-122M	-118M	-126M
Comprehensive Income and Other	-	-2.01M	-1.74M	-1.74M	-1.74M
Total Common Equity	23.33M	-1.76M	-4.57M	4.35M	2.48M
Total Equity	23.33M	-1.76M	-4.57M	9.98M	8.1M
Total Liabilities And Equity	99.6M	27.07M	17.47M	13.45M	11.63M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	188K	328K	464K	853K	3.47M
ECS Total Common Shares Outstanding	188K	328K	464K	853K	3.47M
Book Value / Share	123.94	-5.36	-9.84	5.1	0.71
Tangible Book Value	23.33M	-1.76M	-4.57M	4.35M	2.48M
Tangible Book Value Per Share	123.94	-5.36	-9.84	5.1	0.71
Total Debt	69.74M	21.54M	20.56M	2.09M	2.27M
Net Debt	15.7M	7.47M	15.69M	122K	606K
Debt Equivalent Oper. Leases	-	-	-	-	-
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	3.83M	1.92M	2.46M	9.92M	9.95M
Full Time Employees	15	33	31	31	45

Fiscal Period: December	2021	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-39.98M	-5.8M	-6.5M	4.8M	-8.31M
Depreciation & Amortization - CF	2.42M	562K	514K	1.65M	1.42M
Depreciation & Amortization, Total	2.42M	562K	514K	1.65M	1.42M
(Gain) Loss From Sale Of Asset	-40K	-	-	-	-
Asset Writedown & Restructuring Costs	-	209K	-	-	-
Stock-Based Compensation (CF)	8.9M	1.6M	1.14M	682K	303K
Other Operating Activities, Total	1.87M	-4.11M	-3.74M	-13.57M	389K
Change In Accounts Receivable	162K	140K	-290K	-83K	10K
Change In Accounts Payable	1.24M	-175K	-150K	-156K	31K
Change in Other Net Operating Assets	946K	306K	-356K	351K	122K
Cash from Operations	-24.48M	-7.26M	-9.38M	-6.34M	-6.03M
Capital Expenditure	-430K	-836K	-637K	-12K	-24K
Sale of Property, Plant, and Equipment	40K	-	-	-	-
Investment in Marketable and Equity Securities, Total	-	-	-	-	-
Other Investing Activities, Total	29K	-	-	-	-
Cash from Investing	-361K	-836K	-637K	-12K	-24K
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Long-Term Debt Repaid, Total	-1.22M	-	-	-	-
Total Debt Repaid	-1.22M	-	-	-	-
Issuance of Common Stock	69M	932K	139K	1.44M	5.77M
Other Financing Activities, Total	-	5.84M	947K	2M	-
Cash from Financing	67.78M	6.78M	1.09M	3.44M	5.77M
Foreign Exchange Rate Adjustments	1.68M	-1.98M	-272K	-9K	1K
Net Change in Cash	44.62M	-3.3M	-9.2M	-2.92M	-284K
Supplemental Items
Cash Interest Paid	33K	916K	833K	143K	-
Levered Free Cash Flow	-14.14M	-8.58M	-5.9M	-3.82M	-3.33M
Unlevered Free Cash Flow	-7.37M	-5.52M	-5.9M	-2.93M	-3.1M
Change In Net Working Capital	-3.51M	-61K	854K	-148K	92K
Net Debt Issued / Repaid	-1.22M	-	-	-	-

Fiscal Period: December	2021	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-27.82	-23.39	-27.24	-34.92	-37.6
Return on Total Capital	-29.89	-27.79	-33.91	-38.49	-42.03
Return On Equity %	-915.14	1.49K	205.4	177.37	-91.89
Return on Common Equity	-915.14	1.49K	205.4	0	-243.39
Margin Analysis
Gross Profit Margin %	-	-	-	-88.15	-202.29
SG&A Margin	-	-	-	383.89	192.3
EBITDA Margin %	-	-	-	-1.06K	-466.9
EBITA Margin %	-	-	-	-1.31K	-575.29
EBIT Margin %	-	-	-	-1.31K	-575.29
Income From Continuing Operations Margin %	-	-	-	728.88	-633.64
Net Income Margin %	-	-	-	728.88	-633.64
Net Avail. For Common Margin %	-	-	-	0	-633.64
Normalized Net Income Margin	-	-	-	-946.33	-396.02
Levered Free Cash Flow Margin	-	-	-	-580.62	-253.94
Unlevered Free Cash Flow Margin	-	-	-	-445.55	-236.82
Asset Turnover
Asset Turnover	-	-	-	0.04	0.1
Fixed Assets Turnover	-	-	-	0.06	0.13
Receivables Turnover (Average Receivables)	-	-	-	-	16.81
Short Term Liquidity
Current Ratio	7.64	6.15	3.06	1.32	1.3
Quick Ratio	7.54	6.07	2.94	1.21	1.15
Operating Cash Flow to Current Liabilities	-3.4	-3.11	-5.27	-3.51	-3.81
Days Sales Outstanding (Average Receivables)	-	-	-	-	21.72
Average Days Payable Outstanding	-	-	-	134.66	36.06
Long Term Solvency
Total Debt/Equity	298.88	-1.22K	-450.01	20.91	27.98
Total Debt / Total Capital	74.93	108.9	128.57	17.29	21.86
LT Debt/Equity	295.56	-1.2K	-441.34	16.66	23.92
Long-Term Debt / Total Capital	74.1	106.97	126.09	13.78	18.69
Total Liabilities / Total Assets	76.57	106.5	126.15	25.81	30.3
EBIT / Interest Expense	-3.22	-2.26	-	-6.07	-21.01
EBITDA / Interest Expense	-2.99	-2.15	-	-4.91	-17.05
(EBITDA - Capex) / Interest Expense	-3.03	-2.32	-	-4.92	-17.12
Total Debt / EBITDA	-2.15	-2.05	-2.24	-0.3	-0.37
Net Debt / EBITDA	-0.48	-0.71	-1.71	-0.02	-0.1
Total Debt / (EBITDA - Capex)	-2.12	-1.9	-2.09	-0.3	-0.37
Net Debt / (EBITDA - Capex)	-0.48	-0.66	-1.6	-0.02	-0.1
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-	-	-	99.24
Gross Profit, 1 Yr. Growth %	-	-	-	-	357.24
EBITDA, 1 Yr. Growth %	-476.82	1.04	-12.45	-23.97	-12.42
EBITA, 1 Yr. Growth %	-574.9	1.83	-12.25	-11	-12.69
EBIT, 1 Yr. Growth %	-574.9	1.83	-12.25	-11	-12.69
Earnings From Cont. Operations, 1 Yr. Growth %	797.37	-29.37	12.15	-173.78	-273.21
Net Income, 1 Yr. Growth %	797.37	-29.37	12.15	-173.78	-273.21
Normalized Net Income, 1 Yr. Growth %	797.37	-29.37	12.15	53.28	-16.62
Diluted EPS Before Extra, 1 Yr. Growth %	604.55	-50	-58.4	-	-
Accounts Receivable, 1 Yr. Growth %	-	-	-	-	-12.05
Net Property, Plant and Equip., 1 Yr. Growth %	-3.72	-10.54	-5.29	-8.05	-13.43
Total Assets, 1 Yr. Growth %	75.01	-15.51	-35.45	-23.03	-13.55
Tangible Book Value, 1 Yr. Growth %	-259.86	-279.23	159.6	-195.21	-43.08
Common Equity, 1 Yr. Growth %	-259.86	-279.23	159.6	-195.21	-43.08
Cash From Operations, 1 Yr. Growth %	-66.25	-2.17	29.14	-32.48	-4.8
Capital Expenditures, 1 Yr. Growth %	-92.99	501.44	-23.8	-98.12	100
Levered Free Cash Flow, 1 Yr. Growth %	134.04	216.08	6.88	-53.86	-12.86
Unlevered Free Cash Flow, 1 Yr. Growth %	37.98	103.55	6.88	-50.35	5.9
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-34.1	104.36	-5.95	-18.41	-18.4
EBITA, 2 Yr. CAGR %	-33.33	130.29	-5.47	-11.63	-11.85
EBIT, 2 Yr. CAGR %	-33.33	130.29	-5.47	-11.63	-11.85
Earnings From Cont. Operations, 2 Yr. CAGR %	-39.49	113.89	-11	-9.03	13.05
Net Income, 2 Yr. CAGR %	-39.49	113.89	-11	-9.03	13.05
Normalized Net Income, 2 Yr. CAGR %	-39.49	113.89	-11	31.11	13.05
Diluted EPS Before Extra, 2 Yr. CAGR %	-53.98	87.05	-54.4	-	-53.76
Net Property, Plant and Equip., 2 Yr. CAGR %	2.34	-1.28	-7.95	-6.68	-10.78
Total Assets, 2 Yr. CAGR %	-7.24	29.32	-26.15	-29.51	-18.43
Tangible Book Value, 2 Yr. CAGR %	-40.11	-34.88	115.7	57.21	-26.39
Common Equity, 2 Yr. CAGR %	-40.11	-34.88	115.7	57.21	-26.39
Cash From Operations, 2 Yr. CAGR %	-43.63	-40.66	12.4	-6.62	-19.82
Capital Expenditures, 2 Yr. CAGR %	-75.94	-30.76	114.07	-88.02	-80.59
Levered Free Cash Flow, 2 Yr. CAGR %	-52.82	123.46	47.5	-16.84	-36.59
Unlevered Free Cash Flow, 2 Yr. CAGR %	-63.16	90.74	47.5	-27.15	-27.48
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-24.31	-21.63	55.29	-12.38	-16.46
EBITA, 3 Yr. CAGR %	-23.26	-20.82	68.29	-7.35	-11.98
EBIT, 3 Yr. CAGR %	-23.26	-20.82	68.29	-7.35	-11.98
Earnings From Cont. Operations, 3 Yr. CAGR %	-23.05	-42.85	73.85	-16.39	12.75
Net Income, 3 Yr. CAGR %	-23.05	-42.85	73.85	-16.39	12.75
Normalized Net Income, 3 Yr. CAGR %	-23.05	-42.85	73.85	6.68	12.75
Diluted EPS Before Extra, 3 Yr. CAGR %	-40.47	-52.79	14.23	-	-51.27
Net Property, Plant and Equip., 3 Yr. CAGR %	16.01	1.96	-1.86	-7.99	-8.99
Total Assets, 3 Yr. CAGR %	-2	-6.32	3.4	-25.12	-24.55
Tangible Book Value, 3 Yr. CAGR %	-9.25	-54.35	4.08	64.23	12.05
Common Equity, 3 Yr. CAGR %	-9.25	-54.35	4.08	64.23	12.05
Cash From Operations, 3 Yr. CAGR %	-24.63	-30.79	-22.48	-5.16	-6.02
Capital Expenditures, 3 Yr. CAGR %	-73.74	-26.58	-27.94	-55.8	-69.38
Levered Free Cash Flow, 3 Yr. CAGR %	-37.98	-21.98	52.12	12.08	-15.53
Unlevered Free Cash Flow, 3 Yr. CAGR %	-48.36	-29.01	58.51	2.61	-17.47
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	24.18	9.72	-15.49	-19.8	17.16
EBITA, 5 Yr. CAGR %	23.96	10.46	-14.63	-16.68	26.8
EBIT, 5 Yr. CAGR %	23.96	10.46	-14.63	-16.68	26.8
Earnings From Cont. Operations, 5 Yr. CAGR %	34.2	-10.02	-23.22	-30.69	42.83
Net Income, 5 Yr. CAGR %	34.2	-10.02	-23.22	-30.69	42.83
Normalized Net Income, 5 Yr. CAGR %	34.16	-10.02	-23.22	-19.77	42.83
Diluted EPS Before Extra, 5 Yr. CAGR %	0.82	-27.19	-46.3	-	-22.36
Net Property, Plant and Equip., 5 Yr. CAGR %	98.17	51.96	8.92	-0.89	-7.81
Total Assets, 5 Yr. CAGR %	27.03	3.1	-9.88	-15.8	-8.22
Tangible Book Value, 5 Yr. CAGR %	-1.85	-35.69	-12.02	-24.61	-11.57
Common Equity, 5 Yr. CAGR %	-1.85	-35.69	-12.02	-24.61	-11.57
Cash From Operations, 5 Yr. CAGR %	20.46	20.51	-9.99	-21.43	-23.32
Capital Expenditures, 5 Yr. CAGR %	84.71	-8.2	-37.33	-64.2	-58.39
Levered Free Cash Flow, 5 Yr. CAGR %	21.81	13.61	-18.53	-26.19	11.93
Unlevered Free Cash Flow, 5 Yr. CAGR %	6.92	4.04	-16.85	-27.76	13.14